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Abstract
Background: Mutations in the genes coding for either dystrophin or dysferlin cause distinct forms of muscular
dystrophy. Dystrophin links the cytoskeleton to the sarcolemma through direct interaction with b-dystroglycan. This
link extends to the extracellular matrix by b-dystroglycan’s interaction with a-dystroglycan, which binds
extracellular matrix proteins, including laminin a2, agrin and perlecan, that possess laminin globular domains. The
absence of dystrophin disrupts this link, leading to compromised muscle sarcolemmal integrity. Dysferlin, on the
other hand, plays an important role in the Ca
2+-dependent membrane repair of damaged sarcolemma in skeletal
muscle. Because dysferlin and dystrophin play different roles in maintaining muscle cell integrity, we hypothesized
that disrupting sarcolemmal integrity with dystrophin deficiency would exacerbate the pathology in dysferlin-null
mice and allow further characterization of the role of dysferlin in skeletal muscle.
Methods: To test our hypothesis, we generated dystrophin/dysferlin double-knockout (DKO) mice by breeding
mdx mice with dysferlin-null mice and analyzed the effects of a combined deficiency of dysferlin and dystrophin
on muscle pathology and sarcolemmal integrity.
Results: The DKO mice exhibited more severe muscle pathology than either mdx mice or dysferlin-null mice, and,
importantly, the onset of the muscle pathology occurred much earlier than it did in dysferlin-deficient mice. The DKO
mice showed muscle pathology of various skeletal muscles, including the mandible muscles, as well as a greater
number of regenerating muscle fibers, higher serum creatine kinase levels and elevated Evans blue dye uptake into
skeletal muscles. Lengthening contractions caused similar force deficits, regardless of dysferlin expression. However, the
rate of force recovery within 45 minutes following lengthening contractions was hampered in DKO muscles compared
to mdx muscles or dysferlin-null muscles, suggesting that dysferlin is required for the initial recovery from lengthening
contraction-induced muscle injury of the dystrophin-glycoprotein complex-compromised muscles.
Conclusions: The results of our study suggest that dysferlin-mediated membrane repair helps to limit the
dystrophic changes in dystrophin-deficient skeletal muscle. Dystrophin deficiency unmasks the function of dysferlin
in membrane repair during lengthening contractions. Dystrophin/dysferlin-deficient mice provide a very useful
model with which to evaluate the effectiveness of therapies designed to treat dysferlin deficiency.
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Background
Duchenne muscular dystrophy (DMD) is an X-linked
recessive disease affecting approximately 1 in 3, 500
males and is caused by defects in the dystrophin gene [1].
Dystrophin is an integral component of the dystrophin-
glycoprotein complex (DGC) and is localized to the inner
surface of the plasma membrane [2]. Dystrophin plays an
important role in linking the cytoskeleton to the sarco-
lemma through the direct interactions of its N-terminus
with F-actin and its C-terminus with b-dystroglycan [2].
This link is extended to the extracellular matrix (ECM)
by a-dystroglycan, which binds to laminin a2, agrin and
perlecan with high affinity. The dystrophin-mediated
continuous link between the cytoskeleton and the ECM
is reported to play an important role in stabilizing the
sarcolemmal structure, transmitting force laterally and
* Correspondence: kevin-campbell@uiowa.edu
2Department of Molecular Physiology and Biophysics, Howard Hughes
Medical Institute, Roy J and Lucille A Carver College of Medicine, The
University of Iowa, 285 Newton Road, 4283 CBRB, Iowa City, IA 52242, USA
Full list of author information is available at the end of the article
Han et al. Skeletal Muscle 2011, 1:35
http://www.skeletalmusclejournal.com/content/1/1/35 Skeletal Muscle
© 2011 Han et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.preventing the expansion of muscle membrane damage
during lengthening contraction (LC) [3-8]. In DMD
patients and mdx mice, which also have a mutation in
the dystrophin gene, loss of dystrophin disrupts the link
between the cytoskeleton and the ECM, leading to the
loss of sarcolemmal integrity. This loss of sarcolemmal
integrity eventually results in muscle degeneration,
necrosis and fibrosis. As a consequence, DMD patients
are confined to a wheelchair in their early teens and die
in their early 20s as a result of cardiopulmonary failure
[9].
The plasma membrane provides a physical barrier
between the extracellular space and the intracellular
environment, and maintenance of this barrier is crucial
for the survival of any cell. We previously showed that
skeletal muscle possesses the ability to repair membrane
wounding in a Ca
2+-dependent manner and that dysferlin
plays a critical role in this process [10,11]. Mutations in
dysferlin cause limb-girdle muscular dystrophy type 2B
[12,13], Miyoshi myopathy [13] and a distal anterior
compartment myopathy [14].
Dystrophin deficiency renders the muscle susceptible to
contraction-induced sarcolemmal injuries [4-8], whereas
dysferlin deficiency results in compromised membrane
repair [10,15-19]. Taking into consideration these two dif-
ferent roles in maintaining sarcolemmal integrity, we
hypothesized that skeletal muscle membrane stability
mediated by the DGC and dysferlin-mediated membrane
repair are both essential for the maintenance of muscle
membrane integrity and function. On the basis of this
hypothesis, we predicted that a combined deficiency in
both dysferlin and dystrophin would lead to more severe
muscle pathology due both to an increased susceptibility
to muscle membrane injuries in the absence of dystrophin
and to defective membrane repair in the absence of dysfer-
lin. To test this hypothesis, we generated mice that lack
both dysferlin and dystrophin. The dystrophin/dysferlin
double-knockout (DKO) mice developed more severe
muscle pathology than either mdx mice or dysferlin-null
mice, which is reflected by the higher number of regener-
ated muscle fibers, increased serum creatine kinase (CK)
levels and more Evans blue dye (EBD) uptake in their
muscles. These data show that dysferlin-mediated mem-




The DKO mice were generated by breeding female mdx/
C57BL/10ScSn (mdx) mice with male dysferlin-null mice
[10] through two generations (Additional file 1, Figure S1).
F2 pups were genotyped using recently improved methods
for genotyping the dysferlin allele [20] and the mdx allele
[21] to identify the double-mutant mice. The genetic
background of DKO mice is a mixture of C57/BL6, 129/
SVJ and C57BL/10ScSn. The wild-type (WT) littermates
with the same genetic background were used as controls.
Mice were maintained at The University of Iowa Animal
Care Unit and treated in accordance with animal use
guidelines. All animal studies were authorized by the Ani-
mal Care, Use, and Review Committee of The University
of Iowa.
Serum creatine kinase assay
Using a Microvette CB 300 (Sarstedt AG & Co, Newton,
NC), we collected blood required for quantitative, kinetic
determination of serum CK activity by mouse tail vein
bleeds from nonanesthetized, restrained mice. Red blood
cells were pelleted by centrifugation at 10, 000 rpm for 4
minutes, and serum was separated, collected and analyzed
immediately without freezing. Serum CK assays were per-
formed with an enzyme-coupled assay reagent kit (Stanbio
Laboratory, Boerne, TX, USA) according to the manufac-
turer’s instructions. Absorbance at 340 nm was measured
every 30 seconds for 2 minutes at 37°C so that changes in
enzyme activity could be calculated.
Histological and immunofluorescence analyses
Muscles (masseter, quadriceps, hamstrings, gluteus, gas-
trocnemius, tibialis anterior, iliopsoas and diaphragm)
were dissected and frozen in isopentane cooled to -165°C
in liquid nitrogen. Seven-micron cryosections were cut
and fixed in 10% neutral buffer formalin for five minutes.
After fixation, the slides were washed for five minutes
under running water followed by H & E staining (Surgi-
path Medical Industries, Inc/Leica Microsystems, Rich-
mond, IL, USA). H & E-stained sections were analyzed by
light microscopy (Leica Microsystems Inc, Buffalo Grove,
IL, USA; Carl Zeiss Microscopy, LLC, Thornwood, NY,
USA). Immunofluorescence analyses were also performed
on 7-μm cryosections. Sections were processed for immu-
nofluorescence microscopy and analyzed with an epifluor-
escence microscope (Leica Microsystems Inc, and Carl
Zeiss Microscopy, LLC). Mouse anti-dysferlin (Hamlet-1,
Novocastra, Newcastle, UK) mAb and rabbit pAb against
b-dystroglycan [22], sarcospan [23], dystrophin (Abcam,
Cambridge, MA, USA) and laminin a2 chain (AXXORA
LLC, San Diego, CA, USA) were used for immunofluores-
cence analysis. The central nucleated and total muscle
fibers were counted on muscle sections costained with
anti-laminin a2 antibody and 4’, 6-diamidino-2-phenylin-
dole (Sigma-Aldrich, St Louis, MO, USA) using Image-Pro
Plus version 6 software (Media Cybernetics, Inc, Bethesda,
MD, USA).
Western blot analysis
Proteins were extracted from 20 to 35 cryosections (30 μm
thick) of quadriceps tissue from each mouse using 250 μl
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bitors. The protein samples in the supernatant were mixed
with 80 μl of 5× Laemmli sample buffer, and 70-μlf i n a l
samples were resolved by SDS-PAGE on 3% to 15% linear
gradient gels and transferred onto polyvinylidene fluoride
Immobilon-FL membrane (Millipore, Billerica, MA, USA).
The membranes were blocked with fish gelatin in
Tris-buffered saline (TBS) and incubated with primary
antibodies (mouse anti-dysferlin mAb Hamlet, mouse
anti-b-dystroglycan 8D5 mAb, mouse anti-dystrophin
mAb and rabbit anti-dihydropyridine receptor (anti-
DHPR) a2 pAb [24]). Blots were washed with TBS + 0.1%
Tween 20 and incubated with infrared dye-conjugated sec-
ondary antibodies (Pierce Biotechnology/Thermo Fisher
S c i e n t i f i c ,I n c ,R o c k f o r d ,I L ,U S A ) .A f t e rw a s h i n g ,b l o t s
were captured using the Odyssey Imaging System (LI-
COR, Lincoln, NE, USA).
Evans blue dye uptake
Evans blue dye (Sigma-Aldrich) was dissolved in PBS (10
mg/ml) and sterilized through a 0.2-μm pore size filter.
T h em i c ew e r ea n e s t h e t i z e db yk e t a m i n ei n j e c t i o n( 0 . 1
ml/10 g body weight), and 0.05 ml/10 g body weight dye
solution was injected intraperitoneally. The animals were
killed 24 hours after injection, and their skeletal muscles
were isolated and frozen in isopentane cooled to -165°C
in liquid nitrogen. Microscopic evaluation of EBD uptake
was performed on 7-μm muscle cryosections. Muscle
cryosections were fixed in cold acetone at -20°C for
10 minutes, washed with PBS, coverslipped in VECTA-
SHIELD Mounting Medium (Vector Laboratories,
Burlingame, CA, USA) and evaluated by fluorescence
microscopy.
Force measurement
Contractile properties were measured in vitro on extensor
digitorum longus (EDL) muscles from WT, dysferlin-null,
mdx and DKO mice (12 to 22 weeks of age) as described
previously [3,25]. The mice were anesthetized with an
intraperitoneal injection of 2% avertin (0.0015 ml/g body
weight), and thoracotomy was performed. EDL muscles
were immersed in an oxygenated bath (95% O2,5 %C O 2)
that contained Ringer’s solution (pH 7.4) at 25°C. For each
muscle, one end tendon was tied securely with a 6-0
suture to a dual-mode servomotor (Aurora Scientific, Inc,
Aurora, ON, Canada) and the other tendon was clamped
to a fixed post. Using twitches with a pulse duration of 0.2
milliseconds, the voltage or current of stimulation was
increased to achieve a maximum twitch and then
increased slightly. Twitches were then used to adjust the
muscle length to the optimum length for force develop-
ment (Lo). Fiber length (Lf) was determined by multiplying
Lo by the ratio of fiber length to muscle length (0.45)
[3,25,26]. The muscle length was set at Lo,a n dE D L
muscles were stimulated for 300 milliseconds. The stimu-
lation frequency was increased until the force reached a
plateau at maximum isometric tetanic force (P0). The sus-
ceptibility to LC-induced injury was assessed by subjecting
each muscle to eight LCs at a rate of one LC every three
minutes [3,25,26]. Each LC consisted of maximally activat-
ing the muscle at a fixed length for 100 milliseconds, then
stretching the muscle at a strain of 30% of Lf at a strain a
velocity of 1 Lf/second. Muscle activation ceased upon
achieving the 30% strain and was returned to Lo at the
same velocity. To assess the force deficit generated by this
assay, a measurement of P0 was taken three minutes after
the last LC and repeated at 15, 30 and 45 minutes. The
total fiber cross-sectional area and specific P0 (kN/m
2)
were calculated based on measurements of muscle mass,
Lf and P0. A generalized linear model with repeated-mea-
sures analysis of variance (ANOVA) using SPSS software
(SPSS, Inc, Chicago, IL, USA) was used to determine
whether time after LC, dysferlin and dystrophin were sig-
nificant factors.
Statistics
Data were calculated according to analysis of variance
( A N O V A )a n da r ee x p r e s s e da sm e a n s±S E M .W h e r e
appropriate, the significance of differences between multi-
ple mouse models was assessed using one-way ANOVA
with Student-Newman-Keuls posttests, and the signifi-
cance of differences between two experimental groups
were assessed using an unpaired two-tailed Student’s
t-test. P < 0.05 was accepted as significant.
Results
Disrupted dystrophin and dysferlin expression in skeletal
muscles of DKO mice
Both immunofluorescence and Western blot analyses con-
firmed the complete loss of both dystrophin and dysferlin
in the skeletal muscle membranes of the DKO mice (Fig-
ures 1A and 1B) [15]. Mutations in dystrophin disrupt the
stability of the entire DGC at the sarcolemma, which in
turn renders the muscle susceptible to contraction-
induced injuries [2]. To assess the expression of DGC
components in DKO muscle, we performed immunofluor-
escence and immunoblot experiments using the specific
antibodies against b-dystroglycan and sarcospan, two
DGC components. The WT and dysferlin-null muscles
showed normal expression of b-dystroglycan and sarco-
span (Figures 1A and 1C), suggesting a stable DGC at the
sarcolemma. The mdx and DKO muscles showed a reduc-
tion in the expression of both proteins (Figures 1A and
1C), suggesting a disrupted DGC in the muscles of these
mice. The expression levels of non-DGC proteins DHPR
a2 and laminin a2 were also examined, and we found that
they were not reduced in the DKO muscles (Figures 1A
and 1C).
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Page 3 of 11Figure 1 Disrupted expression of dysferlin and dystrophin in skeletal muscle of dystrophin/dysferlin double-knockout mice. (A)
Western blot showing the expression pattern of dysferlin (DysF), dystrophin (Dyst), b-dystroglycan (b-DG) and dihydropyridine receptor a2
(DHPRa2) in skeletal muscle tissue lysates from wild-type (WT), dysferlin-null, mdx and dystrophin/dysferlin double-knockout (DKO) mice. (B)
Expression of dystrophin and dysferlin in skeletal muscles from WT, dysferlin-null, mdx and DKO mice were examined by immunofluorescence
staining. (C) b-DG and sarcospan (SSPN) were greatly diminished at the sarcolemma of mdx and DKO muscles, but laminin a2 (Lam2) staining
was not reduced. Scale bars: 100 μm.
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Defects in either dysferlin or dystrophin lead to deficits
in skeletal muscle [1,12,13]. Therefore, we carefully
examined the function and histopathology of skeletal
muscles in the DKO mice. We observed that many of
the DKO mice developed malocclusion. Histological
examination of the DKO mandible muscles by H & E
staining revealed greater dystrophic features than either
the mdx or dysferlin-null masseter muscles (Figure 2).
Because rodent incisors grow continuously from birth
and are kept worn down and sharp by continuously
g n a w i n g[ 2 7 ] ,t h em o r es e v e r em u s c l ep a t h o l o g yo ft h e
mandibular muscles in DKO mice suggests increased
muscle weakness of these muscles as a reason for the
long incisor growth. The front teeth of mice with mal-
occlusion were regularly clipped, allowing them access
to and ingestion of food.
The quadriceps muscle sections were also analyzed at
six months of age in DKO mice and compared with the
muscles isolated from age-matched controls, dysferlin-
null and mdx mice. The DKO quadriceps muscle tissues
exhibited more severe muscular dystrophic pathology
compared with dysferlin-null and mdx mice (Figure 3).
Centrally nucleated muscle fibers, which indicate regen-
erating fibers, were quantified in quadriceps muscles
from six-month-old WT, dysferlin-null, mdx and DKO
mice. Of the total muscle fibers, 28% ± 3% in dysferlin-
null mice, 55% ± 2% in mdx mice and 73% ± 2% in DKO
mice were centrally nucleated compared to 1.3% ± 0.2%
in WT mice (six mice per group) (Figure 3B). Muscle his-
topathology of aged DKO mice was also performed,
including the triceps, gastrocnemius, diaphragm, tibialis
anterior, iliopsoas, hamstring and gluteus muscles (Addi-
tional file 2, Figure S2). All muscles from DKO mice
Figure 2 H & E staining of masseter muscle sections from WT, dysferlin-null, mdx and DKO mice at six months of age. Scale bar: 100
μm.
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necrosis, fibrosis and fatty replacement. These results are
consistent with our hypothesis that dystrophin and dys-
ferlin play nonredundant roles in maintaining muscle
function.
Severely compromised muscle sarcolemmal integrity in
the DKO mice
To examine the sarcolemmal integrity of the skeletal
muscle fibers in the DKO mice, we injected EBD and
analyzed its uptake into the quadriceps skeletal muscles.
EBD is a membrane-impermeable dye that binds serum
albumin. A cell can uptake this dye only if the plasma
membrane of the cell is compromised. Therefore, the
presence of EBD-positive fibers indicates the presence of
membrane disruptions in muscle fibers. Individual EBD-
positive muscle fibers were scattered throughout the
muscle sections of dysferlin-null mice, and the muscle
sections of mdx mice showed clusters of EBD-positive
fibers [28] (Figure 4A). Interestingly, the DKO mice
showed both patterns of dye uptake: individual and clus-
ters of EBD-positive muscle fibers (Figure 4A).
Membrane disruptions and muscle damage not only
allow EBD uptake but also lead to leakage of cytosolic
contents such as CK, which can then be detected in the
serum. Measurements of serum CK levels provide an
index of the active skeletal muscle necrosis and the pre-
sence of membrane disruptions. Our analysis revealed
Figure 3 Histopathological analyses of quadriceps muscle sections from DKO mice. (A) H & E-stained quadriceps muscle sections from
dysferlin-null, mdx and DKO mice at six months of age. Scale bar: 100 μm. (B) Quantitative analysis of centrally nucleated muscle fibers (CNF) in
quadriceps muscles from WT, dysferlin-null, mdx and DKO mice (n = 6 per group) at six months of age. Each group was significantly different
from all the other groups. For clarity, significance is shown only for the comparisons with the DKO mice. ***P < 0.001.
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than those of mdx mice and tenfold higher than those
of dysferlin-null mice (Figure 4B). Taken together, these
data suggest that the dystrophin and dysferlin double-
deficiency results in decreased sarcolemmal integrity.
Severe functional deficits in the DKO muscles
To examine whether a double-deficiency of dysferlin
and dystrophin also leads to a more severe functional
disturbance, we measured the force production of EDL
muscles and their responses to LCs. The specific forces
were 219 ± 7 kN/m
2 for WT muscle and 212 ± 8 kN/
m
2 for dysferlin-null muscle, suggesting that the absence
of dysferlin alone does not lead to a deficit of specific
force. The specific forces for mdx mice (166 ± 8 kN/m
2)
were significantly lower than those for WT mice. The
absence of dysferlin had no effect in the mdx back-
ground, as indicated by a lack of significant difference in
specific forces of DKO muscles (153 ± 11 kN/m
2) com-
pared to those of mdx muscles (Figure 5A). However,
dysferlin had a significant role in the force recovery fol-
lowing LCs, particularly in the context of an mdx back-
ground (Figure 5B). Both the WT and dysferlin-null
muscles recovered marginally within 45 minutes post-
Figure 4 Evans blue dye uptake analyses of quadriceps muscles and serum CK measurements. (A) Evans blue dye (EBD) fluorescence
photomicrographs of quadriceps muscle sections from dysferlin-null, mdx and DKO mice at six months of age. Scale bar: 100 μm. (B) Serum
creatine kinase (CK) levels were significantly different (P < 0.001) between DKO mice (n = 6) and the other groups (n = 5, 4 and 6 for WT,
dysferlin-null and mdx mice, respectively). Values for mdx mice were significantly different from those for WT mice (P = 0.018). For clarity,
significance is shown only for the comparisons with the DKO mice. ***P < 0.001.
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minutes; dysferlin-null: 65% ± 4% at 3 minutes vs 71% ±
4% at 45 minutes). Although the force in mdx muscles
was greatly diminished at 3 minutes post-LC, it gradu-
ally recovered from 22% ± 4% at 3 minutes to 61% ± 5%
at 45 minutes (Figure 5B). Interestingly, the DKO mus-
cles also recovered significantly from 16% ± 2% at 3
minutes to 52% ± 1% at 45 minutes (Figure 5B). How-
ever, dysferlin deficiency significantly slowed the recov-
ery of force in the absence of dystrophin (Figure 5B). To
estimate the maximal recovery level and the recovery
rate, we fitted the data to a one-phase association equa-
tion. Particularly, we found that the recovery rate in
DKO muscles (0.032 ± 0.012/minute) was significantly
lower than in mdx muscles (0.080 ± 0.006/minute),
although there was no difference in the maximum
recovery levels (Figures 5C and 5D). These data suggest
that dysferlin deficiency impairs the force recovery fol-
lowing LCs in mdx mice, indicating that compromised
membrane repair [10] has consequences for post-LC
force generation.
Discussion
Skeletal muscle is associated with significant stress and
strain during muscle contraction. Previous studies have
shown at least two mechanisms that skeletal muscle
Figure 5 Effects of dysferlin and dystrophin deficiencies on skeletal muscle contractile properties. We investigated the extensor
digitorum longus (EDL) muscles taken from WT (n = 4), dysferlin-null (n = 6), mdx (n = 8) and DKO mice (n = 3). (A) Tetanic force
measurements prior to LC. *P < 0.05 and **P < 0.01. (B) Tetanic force recovery following LC. Dysferlin deficiency had a significant effect on force
recovery in the absence of dystrophin, as indicated by a significant interaction (P = 0.04) between dysferlin, dystrophin and time after LC on the
basis of analysis of variance. (C) Summary of estimated maximal recovery levels following LC. *P < 0.05. (D) Summary of force recovery rate
following LC. *P < 0.05.
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associated basal lamina mediated by the dystroglycan
complex limits the extent of plasma membrane damage
[3] and membrane repair machinery involving multiple
proteins that actively restore membrane integrity follow-
ing limited levels of membrane disruption, such as dys-
ferlin [10,15,18]; calpain [29]; annexins A1, A2 and A5
[18,30,31]; and MG53 [32,33]. A defect in either
mechanism is detrimental to the muscle, as manifested
by the fact that genetic mutations in either the DGC
components (for review, see [34]) or dysferlin [12-14]
cause various muscular dystrophies. In the present work
using mouse models, we have further demonstrated that
a double-deficiency in both dystrophin and dysferlin
results in more severe muscular dystrophy. The results
of our work are in agreement with those of Shaw et al.
[35], who showed that mice overexpressing the Cox-
sackie virus and adenovirus receptor transgene demon-
strate decreased expression levels of dystrophin and
dysferlin, which may lead to an associated myopathy.
Our work provides genetic evidence that dysferlin and
the DGC are independent pathways for the maintenance
of sarcolemmal integrity in muscle and further high-
lights the importance of these two pathways in muscle
health.
Contraction-induced injury is characterized by two dis-
tinct phases: an initial injury and a delayed secondary
injury from the inflammatory response. The initial injury
consists of mechanical disruption of sarcomeres followed
by impaired excitation-contraction coupling and Ca
2+ sig-
naling and finally by activation of Ca
2+-sensitive degrada-
tion pathways [36]. Interestingly, for muscle with an intact
DGC, whether membrane damage occurs during the initial
injury phase is unclear; but if it exists, it is dysferlin-inde-
pendent [25,37,38]. Several hours to days following the
initial injury, infiltration of inflammatory factors damage
muscle fibers and release reactive oxygen species (ROS),
which aid in clearing disrupted myofibrils but also damage
previously undamaged myofibrils. At this stage, ROS
potentially cause damage to the sarcolemma, possibly
through lipid peroxidation [39,40]. Investigators in pre-
vious studies have demonstrated that dysferlin is impor-
tant in limiting the extent of secondary injury. For
example, three days following a protocol of small strain
LCs, muscles of dysferlin-deficient mice displayed
increased macrophage infiltration, decreased ability to seal
off a membrane-impermeable dye and increased force def-
icits [38,41]. These data indicate that defects in membrane
repair or alteration in repair result in chemoattraction of
immune cells [38,41].
Previously, we demonstrated that a combined defi-
ciency in dysferlin and dystrophin results in the devel-
opment of a pronounced early-onset cardiomyopathy
resembling that seen in DMD patients, in contrast to a
mild, slowly progressing cardiac manifestation in mdx
mice [15]. Thus the DKO mouse model is well-suited
to the study of the molecular mechanisms of and ther-
apy for cardiomyopathy in DMD. Our present study
reveals for the first time that dystrophin deficiency
unmasks a role for dysferlin in repairing membrane
damage during the initial injury elicited by LCs. Com-
pared to WT skeletal muscle, mdx muscle had a much
greater force deficit measured three minutes after LC
(78% in mdx vs 31% in WT). However, by 45 minutes,
the force in mdx muscles recovered from 22% to over
60% of the preinjury level, whereas the WT and dysfer-
lin-null muscles gained only 10% (from 69% to 79%)
and 6% (from 65% to 71%), respectively. These data
suggest that, unlike WT and dysferlin-null muscle, in
which LCs induce little membrane damage, mdx muscle
undergoes more severe membrane damage, which
requires an active membrane repair process to restore
membrane integrity. DKO muscles are also repair-com-
petent, as the force also recovered from 16% at 3 min-
utes to 52% at 45 minutes. However, by comparing the
recovery rate constants of mdx muscles and DKO mus-
cles, we found that the recovery rate of the DKO mus-
cles was less than half the rate of mdx muscles.
Therefore, our data derived from using a LC assay
reveal that dystrophin deficiency sufficiently unmasks
the membrane repair role of dysferlin. The DKO mouse
would be a very useful model with which to determine
the efficacy of a therapeutic treatment designed for
dysferlinopathy.
Conclusion
Taken together, our results show that both DGC-
mediated membrane stability and dysferlin-mediated
membrane repair contribute to the function and mainte-
nance of skeletal muscle. The studies presented here
s u g g e s tt h a tt h eD K Om o u s em o d e lm a yb eav a l u a b l e
tool in the development of therapies designed to treat
dysferlinopathies.
Additional material
Additional file 1: Figure S1 Breeding strategy to generate
dystrophin/dysferlin double-knockout mice. Male dysferlin-null mice
were mated with mdx female mice, then F1 heterozygous males and
females were bred to generate F2 males and females. Of the F2 males
and females, 12.5% are predicted to be DKO mice.
Additional file 2: Figure S2 Histopathology analyses of various
muscles from dystrophin/dysferlin double-knockout mice.H&E -
stained muscle sections of triceps (TC), gastrocnemius (GA), diaphragm
(DIA), tibialis anterior (TA), iliopsoas (IP), hamstring (HS) and gluteus (GT)
muscles from dystrophin/dysferlin double-knockout (DKO) mice at one
and one-half years of age. Scale bar: 100 μm.
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CK: creatine kinase; DGC: dystrophin-glycoprotein complex; DHPR:
dihydropyridine receptor; DKO: dystrophin/dysferlin double-knockout; DMD:
Duchenne muscular dystrophy; EBD: Evans blue dye; ECM: extracellular
matrix; EDL: extensor digitorum longus; H & E: hematoxylin and eosin; LC:
lengthening contraction; mAb: monoclonal antibody; pAb: polyclonal
antibody; PBS: phosphate-buffered saline; ROS: reactive oxygen species.
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